Acusphere competitors

Marc’s career in pharmaceuticals, which has included periods with Roussel Uclaf, Hoechst Marion Roussel and GlaxoSmithKline (GSK), has given him extensive industry experience, including finance and accounting; corporate strategy and planning; research and development; sales and marketing; business reorganisation; and business development. Marc is a qualified accountant and joined AstraZeneca in 2013, serving as Executive Vice-President, GPPS from June to October 2013. Prior to that, he served as Global Head of Rare Diseases at GSK and (concurrently) Chairman, GSK Japan. He holds an MBA from HEC, Paris and a Bachelor of Law degree from Paris University.

Howard Robin joined Nektar Therapeutics in January 2007. He has more than 25 years of successful biopharmaceutical experience managing clinical development and commercial operations. Most recently, Mr. Robin served as President and Chief Executive Officer of Sirna Therapeutics, a clinical-stage biotechnology company pioneering RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration (AMD), hepatitis C, asthma, respiratory syncytial virus (RSV) and Huntington's disease. During his tenure at Sirna, Mr. Robin successfully re-launched the company and created significant shareholder value that led to its acquisition by Merck for $1.1 billion. Prior to Sirna, Mr. Robin spent 20 years at Berlex Laboratories, the U.S. pharmaceutical subsidiary of the German pharmaceutical firm Schering AG. From 1991 to 2001, he served as corporate vice president and general manager of their U.S. Therapeutics division and was responsible for the development of drugs, such as Betaseron® (Interferon beta-1b) for multiple sclerosis and Fludara® (fludarabine phosphate) for chronic lymphocytic leukemia, generating annual global sales in excess of $800 million. He also served as a member of the Executive Committee. Prior to that, he was vice president of Finance and Business Development and CFO of Berlex. Earlier in his career, Mr. Robin was a senior associate with Arthur Andersen and Co. Mr. Robin serves as a director of the Biotechnology Industry Organization, the world's largest biotechnology industry trade organization. Mr. Robin holds a B.S. in Accounting and Finance from Fairleigh Dickinson University in New Jersey and serves as a member of its Board of Trustees.

Experienced MedTech Executive with 25+ years of experience including roles as a senior executive, CEO (public and private companies), Founder/entrepreneur, Venture Capitalist and Board Member/Executive Chairman/Chairman. Served as Chairman, President and Chief Executive Officer of ZELTIQ Aesthetics (ZLTQ) from April of 2012 until the Company's acquisition by Allergan for $2.5B in April of 2017. Initially, I joined ZELTIQ in 2009 as Executive Chairman and as a member of the Board of Directors. Currently, I am a Managing Director at RWI Ventures, serve as Chairman of the Board for ULab, HintMD and Arrinex and am a board member at Glaukos (GKOS) and Revance (RVNC). Prior to this, I served on the boards of several private companies, held operating roles in large, public companies and venture-backed start-ups including US Surgical Corporation, Guidant Corporation, Devices for Vascular Intervention (acquired by Eli Lilly), Perclose (acquired by Abbott) and Ventrica (acquired by Medtronic) where I was the founder and CEO. I received my B.A. from the University of Notre Dame (1987) and am a named inventor on 17 patent applications.

Laurence J.N. Cooper transitioned from CEO to Scientific Advisor in February of 2021. Laurence joined Ziopharm Oncology as chief executive officer in 2015 after the Company licensed technology for a non-viral approach for genetically modifying T cells from MD Anderson Cancer and the University of Minnesota. This technology is designed to reduce the cost and complexity of genetically modified T cells. Prior to joining Ziopharm, Laurence was a tenured Professor at MD Anderson with joint appointments in the Division of Pediatrics and Department of Immunology. There, he served as Section Chief of Cell Therapy at the Children’s Cancer Hospital and helped lead scientific efforts to develop new treatment approaches which pair genetic engineering with immunotherapies. He remains a visiting scientist at MD Anderson. Laurence has coauthored dozens of peer-reviewed journal articles, abstracts, and book chapters. He has initiated multiple trials under INDs infusing T cells and NK cells. He obtained his M.D. and Ph.D. degrees at Case Western Reserve University in Cleveland and he completed his training in Pediatric Oncology and Bone Marrow Transplantation at the Fred Hutchinson Cancer Research Center in Seattle.

Heather Manchin Bresch (Manchin; born June 27, 1969) is an American business executive. In 2012, she was named as the chief executive officer (CEO) of Netherlands-based pharmaceutical company Mylan, becoming the first woman to run a Fortune 500 pharmaceutical company. Bresch retired in 2020, upon the closing of Mylan’s combination with Upjohn. In 2015, she was listed as #22 in Fortune magazine's “Most Powerful Women” list.

Richard L Feinstein is a VP:Finance/CFO at ENZON PHARMACEUTICALS, INC.; Chief Financial Officer at USA Fitness Corps; and Board Member at USA Fitness Corps and is based in Greater New York City Area. He has worked as VP:Finance/Principal Financial Ofcr at ENZON PHARMACEUTICALS, INC.; Partner at KPMG; and CFO/Consultant at ImageProtect. Richard works or has worked as MEMBER at Association For A Better New York. He studied at Pace University.

Wang Yan are a Chief Executive Officer at Cytovance Biologics, President at Scientific Protein Labs Llc, and Board Member at Cytovance Biologics. They have worked as VP:Business Development at Scientific Protein Labs Llc.